e-learning
resources
Virtual 2021
07.09.2021
Advances in diagnosis, treatment and clinical management of nontuberculous mycobacterial disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Interferon gamma (IFN?) pathway deficiency and severe NTM disease
S. Sharma (Woking Surrey, United Kingdom), F. Ali (Woking Surrey, United Kingdom), S. Sujoy (Woking Surrey, United Kingdom), K. Jola (Woking Surrey, United Kingdom)
Source:
Virtual Congress 2021 – Advances in diagnosis, treatment and clinical management of nontuberculous mycobacterial disease
Session:
Advances in diagnosis, treatment and clinical management of nontuberculous mycobacterial disease
Session type:
E-poster
Number:
3086
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Sharma (Woking Surrey, United Kingdom), F. Ali (Woking Surrey, United Kingdom), S. Sujoy (Woking Surrey, United Kingdom), K. Jola (Woking Surrey, United Kingdom). Interferon gamma (IFN?) pathway deficiency and severe NTM disease. 3086
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
What is the best test to detect latent tuberculosis infection in sarcoidosis patients? – Comparison between two commercially available interferon gamma release assays
Source: Annual Congress 2013 –Diffuse parenchymal lung disease III
Year: 2013
Tuberculin skin test or interferon gamma release assay - How to detect latent tuberculosis infection in sarcoidosis patients?
Source: International Congress 2015 – Sarcoidosis: clinical
Year: 2015
Interferon gamma release assays based on M. tuberculosis-specific antigens (IGRAs) in sarcoidosis patients
Source: International Congress 2015 – Sarcoidosis: pathogenesis
Year: 2015
Inhaled IFN-γ for persistent nontuberculous mycobacterial pulmonary disease due to functional IFN-γ deficiency
Source: Eur Respir J 2004; 24: 367-370
Year: 2004
Aerosol delivery of an immunomodulator (interferon-γ 1b) within mouse lungs
Source: International Congress 2015 – Interstitial lung diseases I
Year: 2015
Significance of interferon gamma-inducible chemokines in pleural effusions
Source: International Congress 2015 – Biomarkers in TB: immunology and physiology
Year: 2015
Interferon gamma release assays in screening for tuberculosis – Can we use them in patients with sarcoidosis?
Source: Annual Congress 2011 - Different profiles of sarcoidosis and other granulomatous disorders
Year: 2011
A combinatorial dual-immunoassay predicts reactivation risk for patients with previously incomplete treatment for latent tuberculosis infection
Source: International Congress 2016 – Active and latent tuberculosis: biomarkers
Year: 2016
Initiation of anti-TNF therapy within 3 weeks of LTBI treatment in patients with immune-mediated inflammatory diseases
Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 3
Year: 2014
Diagnosing latent tuberculosis in immunocompromised patients measuring blood IP-10 production capacity: An analysis of chronic renal faulire patients
Source: International Congress 2015 – Screening strategies in TB
Year: 2015
Evolution of previous sarcoidosis under type 1 interferons given for severe associated disease
Source: Eur Respir J 2005; 25: 570-573
Year: 2005
TGF-β 1 suppresses IRF-1 expression in pulmonary fibroblasts and modulates its induction by IFN α and IFN γ
Source: Annual Congress 2011 - Lung cell injury and repair
Year: 2011
Interferon (-alpha, -beta, and -omega) receptor 2 (IFNAR2) is a prognostic biomarker for lung cancer
Source: Annual Congress 2011 - Innovative diagnostic methods for lung cancer
Year: 2011
CD8-response associates with active tuberculosis and TB2-tube response in the QuantiFERON-TB-Plus kit
Source: International Congress 2016 – Tuberculosis: immune responses of CD8+ T cells, value of interferon-gamma and other cytokines, Th2 responses, BCG, and biomarkers
Year: 2016
Genetic tendency for developing tuberculosis: 8 patients with IL-12 receptor β1 deficiency
Source: Eur Respir J 2004; 24: Suppl. 48, 397s
Year: 2004
Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis
Source: Eur Respir J 2006; 28: 496-504
Year: 2006
Lung expression of interleukin-13 (IL-13) and interferon gamma (IFNg) in emphysema in human
Source: Eur Respir J 2002; 20: Suppl. 38, 584s
Year: 2002
Treatment of Idiopathic pulmonary fibrosis with interferon beta - our experience in seven patients
Source: Eur Respir J 2003; 22: Suppl. 45, 44s
Year: 2003
HLA-DRB homozygosity negatively affects the Interferon gamma release assay response to Mycobacterium tuberculosis antigens
Source: International Congress 2017 – Human susceptibility to tuberculosis
Year: 2017
An evaluation of the use of a negative interferon gamma release assay for tuberculosis screening before TNF antagonist therapy
Source: Eur Respir J 2014; 44: 1369-1372
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept